These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15943041)

  • 1. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma.
    Jablkowski M; Bocian A; Bialkowska J; Bartkowiak J
    J Exp Clin Cancer Res; 2005 Mar; 24(1):117-25. PubMed ID: 15943041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
    Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of functional inactivation of p53 from MDM2 overexpression in hepatocarcinogenesis].
    Luo YL; Cheng RX; Feng DY
    Hunan Yi Ke Da Xue Xue Bao; 2001 Feb; 26(1):13-6. PubMed ID: 12536604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
    Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
    J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
    Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
    Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
    Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
    Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
    Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
    Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
    J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
    Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
    Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus-NS3P in relation to p53, p21waf, mdm2, p21-ras and c-erbB2 in hepatocarcinogenesis.
    Bahnassi AA; Zekri AR; El-Houssini S; Mokhtar NM; Abdel-Aziz AO; Sherif GM; El-Mishad AM; Khaled HM
    J Gastroenterol Hepatol; 2005 Nov; 20(11):1731-40. PubMed ID: 16246194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal expression of MDM2 in prostate carcinoma.
    Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
    Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
    Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
    Koga T; Hashimoto S; Sugio K; Yoshino I; Nakagawa K; Yonemitsu Y; Sugimachi K; Sueishi K
    Int J Cancer; 2001 Jul; 95(4):232-9. PubMed ID: 11400116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours.
    Yamamoto H; Oda Y; Saito T; Sakamoto A; Miyajima K; Tamiya S; Tsuneyoshi M
    Histopathology; 2003 May; 42(5):431-9. PubMed ID: 12713619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
    Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
    J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
    Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
    Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2-p53 pathway in hepatocellular carcinoma.
    Meng X; Franklin DA; Dong J; Zhang Y
    Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
    Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M
    Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.